Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs NNC 0174 0833 (Primary) ; Semaglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 07 Nov 2019 Planned number of patients changed from 80 to 96.
- 07 Nov 2019 Planned End Date changed from 22 Jan 2020 to 31 Jan 2020.
- 07 Nov 2019 Status changed from active, no longer recruiting to recruiting.